NASDAQ: INMB · Life Sciences · 4 alerts · CIK 1711754
Share price
$0.9464Close, Nov 16
Market cap
$29.3M
Shares outstanding
30.96MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Inmune Bio, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, INmune Bio reported a net loss of $11.4 million, a significant reduction from the $40.7 million loss in the prior year period which included a $16.5 million impairment charge. The company reported zero revenue for the 2026 period and expressed substantial doubt about its ability to continue as a going concern due to insufficient liquidity to sustain operations for the next twelve months.
INmune Bio Inc. entered into a securities purchase agreement with a single institutional investor for a $4.5 million registered direct offering and concurrent private placement. The company is issuing 3,000,000 shares of common stock at $1.50 per share along with warrants to purchase an additional 3,000,000 shares at an exercise price of $1.65. Proceeds are intended for working capital and general corporate purposes.
INmune Bio filed a formal investor presentation deck and announced a Master Services Agreement with Uniphar to establish a commercialization framework for Ebstrocel. The partnership will initially focus on named-patient access in Europe and the MENA region, providing a capital-efficient infrastructure for international distribution. Additionally, the company submitted a pre-Marketing Authorisation Application to the UK MHRA for Ebstrocel.